Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gepirone ER “not approvable” for third time

Executive Summary

FDA deems Fabre-Kramer Pharmaceuticals' gepirone ER "not approvable" for treatment of adults with major depressive disorder, firm says Nov. 2. FKP submitted an amendment to the NDA for the potential first-in-class 5HT1a agonist in May with data that FDA requested in a 2004 "not approvable" notice received by then-licensee Organon. The drug was to be marketed by GlaxoSmithKline under an agreement inked by the companies in February. The partners said they are evaluating FDA's response "to determine appropriate next steps." FKP reacquired rights to gepirone ER from Organon in 2005. Organon had withdrawn its application for the drug after receiving two "not approvable" letters, in 2002 and 2004 (1"The Pink Sheet" June 28, 2004, In Brief)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS049000

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel